Leap Therapeutics Inc (OQ:LPTX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 47 Thorndike St Ste B1-1
CAMBRIDGE MA 02141-1799
Tel: N/A
Website: https://www.leaptx.com
IR: See website
<
Key People
Christopher K. Mirabelli
Chairman of the Board
Douglas E. Onsi
President, Chief Executive Officer, Director
Augustine J. Lawlor
Chief Operating Officer
Jason Baum
Chief Scientific Officer
Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Mark O'Mahony
Chief Manufacturing Officer
Cynthia Sirard
Chief Medical Officer
   
Business Overview
Leap Therapeutics, Inc. is a biotechnology company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and promotes tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. The Company's pipeline includes FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Claudin18.2 regulates barrier properties and contributes to cell-to-cell adhesion. It also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15.
Financial Overview
For the fiscal year ended 31 December 2023, Leap Therapeutics Inc revenues was not reported. Net loss increased 49% to $81.4M. Higher net loss reflects General and Administrative - Balancing increase of 24% to $11.3M (expense), Australian research and development ince decrease of 46% to $1.1M (income), Stock-based Compensation in R&D increase of 4% to $2.6M (expense).
Employees: 54 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $0.53M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$57.44M as of Dec 31, 2023
Net annual income (TTM): -$81.41M as of Dec 31, 2023
Free cash flow (TTM): -$43.75M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 25,600,137 as of Mar 13, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.